Expecting? On XOLAIR®? ENROLL in the EXPECT Pregnancy Registry. XOLAIR® (omalizumab) for subcutaneous use.

Now Enrolling

An observational Pregnancy Registry is under way to evaluate pregnancy outcomes in women who have received XOLAIR prior to conception or at any time during pregnancy. If you are pregnant and have received XOLAIR (also called omalizumab) you may qualify to participate. The EXPECT Pregnancy Registry seeks participants who:

You do not have to be taking XOLAIR now to be eligible.

If eligible, you will be asked to participate in a telephone interview each trimester, at the time of delivery, and every 6 months until your baby is 1 year old. No clinic visits are required. After your baby is born, if you continue to take XOLAIR while breastfeeding, you will be asked to participate in one more telephone interview when your baby is 18 months old. Eligible participants will be compensated for each telephone interview.

To see if you may qualify for the EXPECT Registry, call us at 1-(866)-4XOLAIR (1-866-496-5247), Option 3 or click here.

Who is XOLAIR® for?
XOLAIR® (omalizumab) for subcutaneous use is an injectable, prescription medicine for patients ages 12 and older. It is for patients with moderate to severe persistent allergic asthma caused by year-round allergens in the air. A skin or blood test is done to see if you have allergic asthma. XOLAIR is for patients who are not controlled by asthma medicines called inhaled steroids.

XOLAIR helps reduce the number of asthma attacks in people with allergic asthma who still have asthma symptoms even though they are taking inhaled steroids.

Important Limitations of Use


XOLAIR should always be injected in a doctor's office. You should read the Medication Guide before starting XOLAIR treatment and before each and every treatment.

A severe allergic reaction called anaphylaxis has happened in some patients after they received XOLAIR. Anaphylaxis is a life-threatening condition and can lead to death. Seek emergency medical treatment right away if symptoms occur. Signs and symptoms of anaphylaxis include:

You should not receive XOLAIR if you have ever had an allergic reaction to a XOLAIR injection. Do not use XOLAIR if you are allergic to any of its ingredients.

In clinical studies 0.5% of patients receiving XOLAIR developed cancer, compared to 0.2% of patients receiving placebo (an injection with no active medicine).

Joint inflammation or pain, rash, fever, and swollen lymph nodes have been seen in patients taking XOLAIR. Talk to your doctor if you’ve experienced any of these signs and symptoms.

In patients ≥ 12 years of age, the most commonly observed side effects in asthma studies that had a ≥ 1% difference between XOLAIR and placebo were joint pain (8%), pain (general) (7%), leg pain (4%), tiredness (fatigue) (3%), dizziness (3%), fracture (2%), arm pain (2%), itching (2%), inflammation of the skin (2%), and earache (2%).

In asthma studies, the most common side effects in patients, who either needed to stop XOLAIR or needed medical attention, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and sore throat (11%). These side effects were seen at the same rates in XOLAIR-treated patients as in patients in the control group who received placebo.

XOLAIR is not a rescue medicine and should not be used to treat sudden asthma attacks.

XOLAIR is not a substitute for the medicines you are already taking. Do not change or stop taking any of your other asthma medicines unless your doctor tells you to do so. You may not see an immediate improvement in your asthma when beginning XOLAIR therapy.

Talk to your doctor for more information and if you have any questions about your treatment.

You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by calling 1-800-FDA-1088.

You may also report any side effects to 1-866-4XOLAIR (1-866-496-5247), Option 3.

Please see full Prescribing Information, including Medication Guide for additional important safety information.